{
    "clinical_study": {
        "@rank": "48755", 
        "acronym": "AIMS", 
        "arm_group": [
            {
                "arm_group_label": "Mirasol", 
                "arm_group_type": "Experimental", 
                "description": "Mirasol-treated whole blood"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Untreated control whole blood"
            }
        ], 
        "brief_summary": {
            "textblock": "The trial will evaluate the efficacy of the Mirasol Pathogen Reduction Technology for Whole\n      Blood to prevent Malaria transmission by transfusion of whole blood."
        }, 
        "brief_title": "Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years\n\n          -  Patient is blood group O+\n\n          -  Anticipated to be hospitalized for at least 3 consecutive days after initial study\n             transfusion\n\n          -  Expected to require no more than 2 units of Fresh Whole Blood in the 3 days following\n             randomization\n\n          -  Agree to return to the hospital for the follow-up visits\n\n          -  Women of Child Bearing Potential must have a negative pregnancy test within 72 hours\n             before randomization when warranted and must agree to practice a medically acceptable\n             contraception regimen or agree to abstain from heterosexual intercourse during their\n             study participation.\n\n          -  Patient or legally authorized representative has given written informed consent\n\n        Exclusion Criteria:\n\n          -  Symptoms of clinical malaria (confirmed by microscopy)\n\n          -  Patient has received antimalarial treatment within 7 days prior to randomization\n\n          -  Fever (Central body temperature greater than 38.5\u00b0C)\n\n          -  Massive bleeding expected to require more than two Fresh Whole Blood units within 3\n             days from randomization\n\n          -  Transfusion(s) of a blood product within 1 month prior to randomization\n\n          -  Acute or chronic medical disorder that, in the opinion of the investigator, would\n             impair the ability of the patient to receive protocol treatment\n\n          -  Previous treatment with other pathogen-reduced blood products\n\n          -  Females who are pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118428", 
            "org_study_id": "CTS-5031"
        }, 
        "intervention": {
            "arm_group_label": "Mirasol", 
            "description": "Mirasol Pathogen Reduction Technology System for Whole Blood", 
            "intervention_name": "Mirasol", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "whole blood", 
            "transfusion", 
            "Plasmodium", 
            "Malaria", 
            "Pathogen Reduction Technology", 
            "Whole blood transfusion"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "contact": {
                "email": "sowusu-ofori@kathhsp.org", 
                "last_name": "Shirley Owusu-Ofori, MBCHB, CTM, FGCP", 
                "phone": "00233 20 817 8099"
            }, 
            "facility": {
                "address": {
                    "city": "Kumasi", 
                    "country": "Ghana"
                }, 
                "name": "Komfo Anokye Teaching Hospital"
            }, 
            "investigator": {
                "last_name": "Shirley Owusu-Ofori, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Ghana"
        }, 
        "number_of_arms": "2", 
        "official_title": "AIMS Study: African Investigation of Mirasol System for Whole Blood. Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria", 
        "other_outcome": [
            {
                "measure": "Transfusion reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Within 28 days post-transfusion"
            }, 
            {
                "measure": "Treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 28 days post-transfusion"
            }
        ], 
        "overall_contact": {
            "email": "liesbeth.deberdt@terumobct.com", 
            "last_name": "Liesbeth Deberdt", 
            "phone": "+32 2 715 05 39"
        }, 
        "overall_official": {
            "affiliation": "Komfo Anokye Teaching Hospital", 
            "last_name": "Shirley Owusu-Ofori, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ghana : Food and Drugs Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Transfusion-transmitted Malaria", 
            "safety_issue": "No", 
            "time_frame": "Within 28 days post-transfusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118428"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Bacterial contamination of Fresh Whole Blood products, possible transfusion-transmission in patients presenting with fever", 
                "safety_issue": "No", 
                "time_frame": "Within 28 days post-transfusion"
            }, 
            {
                "measure": "Hematological parameters (red blood cell count, white blood cell count, hemoglobin, hematocrit, platelet count) in Fresh Whole Blood products and in patients", 
                "safety_issue": "No", 
                "time_frame": "Within 28 days post-transfusion"
            }, 
            {
                "measure": "Transmission rates in subpopulation of prior non-parasitemic subjects receiving parasitemic Fresh Whole Blood products", 
                "safety_issue": "No", 
                "time_frame": "Within 28 days post-transfusion"
            }, 
            {
                "measure": "Biochemistry parameters (potassium) in Fresh Whole Blood products and in patients", 
                "safety_issue": "No", 
                "time_frame": "Within 28 days post-transfusion"
            }, 
            {
                "measure": "Coagulation parameters (PT, aPTT, INR) in Fresh Whole Blood products and in patients", 
                "safety_issue": "No", 
                "time_frame": "Within 28 days post-transfusion"
            }
        ], 
        "source": "Terumo BCTbio", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Terumo BCTbio", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}